Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 4, 2021
Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clinical DevelopmentBioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of...
-
Sep 5, 2021BioMarin Also Pausing Further Enrollment of Additional Participants Outside the U.S. in Phearless Phase 1/2 Study
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study. The Phearless study is...
-
Aug 27, 2021Achondroplasia is the Most Common Cause of Dwarfism
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoritide), a once daily injection to treat...
-
Aug 25, 2021- Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 1:15pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences. An audio webcast of the presentations will be available...
-
Jul 28, 2021- Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 % Change 2021 2020 % Change Total Revenues $ 501.7